Prof. Dr. Christoph Driessen
Medizinische Onkologie und Hämatologie · Dept. I
The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L, Kraus M, Besse A, Driessen C, Tarantino I. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma. Sci Rep 2023; 13:4411.
Mar 17, 2023The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Mar 17, 2023Sci Rep 2023; 13:4411
Besse Lenka, Kraus Marianne, Besse Andrej, Driessen Christoph, Tarantino Ignazio
Acupuncture in chemotherapy-induced dysgeusia (AcuDysg): study protocol of a randomised controlled trial.
Huber C, Zhang L, Schlaeppi M, Müller T, Roll S, Voiss P, Barth J, Driessen C, Witt C. Acupuncture in chemotherapy-induced dysgeusia (AcuDysg): study protocol of a randomised controlled trial. BMJ Open 2023; 13:e066137.
Mar 10, 2023Acupuncture in chemotherapy-induced dysgeusia (AcuDysg): study protocol of a randomised controlled trial.
Mar 10, 2023BMJ Open 2023; 13:e066137
Huber Christine, Zhang Linxin, Schlaeppi Marc, Müller Twyla, Roll Stephanie, Voiss Petra, Barth Jürgen, Driessen Christoph, Witt Claudia M
High-dose carfilzomib achieves superior anti-tumor activity over lowdose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Zhou X, Besse A, Peter J, Steinhardt M, Vogt C, Nerreter S, Teufel E, Stanojkovska E, Xiao X, Hornburger H, Haertle L, Lopez M, Munawar U, Riedel A, Han S, Maurits E, Overkleeft H, Florea B, Einsele H, Kortüm K, Driessen C, Besse L, Rasche L. High-dose carfilzomib achieves superior anti-tumor activity over lowdose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex. Haematologica 2023
Feb 2, 2023High-dose carfilzomib achieves superior anti-tumor activity over lowdose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Feb 2, 2023Haematologica 2023
Zhou Xiang, Besse Andrej, Peter Jessica, Steinhardt Maximilian Johannes, Vogt Cornelia, Nerreter Silvia, Teufel Eva, Stanojkovska Emilia, Xiao Xianghui, Hornburger Hannah, Haertle Larissa, Lopez Max Mendez, Munawar Umair, Riedel Angela, Han Seungbin, Maurits Elmer, Overkleeft Herman S, Florea Bogdan, Einsele Hermann, Kortüm K Martin, Driessen Christoph, Besse Lenka, Rasche Leo
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Núñez N, Berner F, Friebel E, Unger S, Wyss N, Gomez J, Purde M, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou M, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto P, Dummer R, Jäger E, Driessen C, Levesque M, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (N Y) 2023
Jan 13, 2023Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Jan 13, 2023Med (N Y) 2023
Núñez Nicolás Gonzalo, Berner Fiamma, Friebel Ekaterina, Unger Susanne, Wyss Nina, Gomez Julia Martinez, Purde Mette-Triin, Niederer Rebekka, Porsch Maximilian, Lichtensteiger Christa, Kramer Rafaela, Erdmann Michael, Schmitt Christina, Heinzerling Lucie, Abdou Marie-Therese, Karbach Julia, Schadendorf Dirk, Zimmer Lisa, Ugurel Selma, Klümper Niklas, Hölzel Michael, Power Laura, Kreutmair Stefanie, Capone Mariaelena, Madonna Gabriele, Cevhertas Lacin, Heider Anja, Amaral Teresa, Hasan Ali Omar, Bomze David, Dimitriou Florentia, Diem Stefan, Ascierto Paolo Antonio, Dummer Reinhard, Jäger Elke, Driessen Christoph, Levesque Mitchell Paul, van de Veen Willem, Joerger Markus, Früh Martin, Becher Burkhard, Flatz Lukas
Mutant driving the Warburg Effect in Mantle Cell lymphoma.
Kliebhan J, Besse A, Kampa-Schittenhelm K, Schittenhelm M, Driessen C. Mutant driving the Warburg Effect in Mantle Cell lymphoma. Clin Case Rep 2022; 10:e6296.
Oct 3, 2022Mutant driving the Warburg Effect in Mantle Cell lymphoma.
Oct 3, 2022Clin Case Rep 2022; 10:e6296
Kliebhan Johannes, Besse Andrej, Kampa-Schittenhelm Kerstin M, Schittenhelm Marcus, Driessen Christoph
Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
Ferguson I, Lin Y, Lam C, Shao H, Tharp K, Hale M, Kasap C, Mariano M, Kishishita A, Patiño Escobar B, Mandal K, Steri V, Wang D, Phojanakong P, Tuomivaara S, Hann B, Driessen C, Van Ness B, Gestwicki J, Wiita A. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma. Cell Chem Biol 2022; 29:1288-1302.e7.
Jul 18, 2022Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
Jul 18, 2022Cell Chem Biol 2022; 29:1288-1302.e7
Ferguson Ian D, Lin Yu-Hsiu T, Lam Christine, Shao Hao, Tharp Kevin M, Hale Martina, Kasap Corynn, Mariano Margarette C, Kishishita Audrey, Patiño Escobar Bonell, Mandal Kamal, Steri Veronica, Wang Donghui, Phojanakong Paul, Tuomivaara Sami T, Hann Byron, Driessen Christoph, Van Ness Brian, Gestwicki Jason E, Wiita Arun P
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Ferguson I, Patiño-Escobar B, Tuomivaara S, Lin Y, Nix M, Leung K, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong S, Wolf J, Martin T, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey A, Mullins R, Eyquem J, Wells J, Wiita A. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun 2022; 13:4121.
Jul 15, 2022The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Jul 15, 2022Nat Commun 2022; 13:4121
Ferguson Ian D, Patiño-Escobar Bonell, Tuomivaara Sami T, Lin Yu-Hsiu T, Nix Matthew A, Leung Kevin K, Kasap Corynn, Ramos Emilio, Nieves Vasquez Wilson, Talbot Alexis, Hale Martina, Naik Akul, Kishishita Audrey, Choudhry Priya, Lopez-Girona Antonia, Miao Weili, Wong Sandy W, Wolf Jeffrey L, Martin Thomas G, Shah Nina, Vandenberg Scott, Prakash Sonam, Besse Lenka, Driessen Christoph, Posey Avery D, Mullins R Dyche, Eyquem Justin, Wells James A, Wiita Arun P
Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
Schwestermann J, Besse A, Driessen C, Besse L. Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. Front Oncol 2022; 12:899272.
May 26, 2022Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
May 26, 2022Front Oncol 2022; 12:899272
Schwestermann Jonas, Besse Andrej, Driessen Christoph, Besse Lenka
Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting.
Lalive d'Epinay M, Güsewell S, Graf N, Mey U, Driessen C, Hitz F. Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting. Hematol Oncol 2022; 40:716-723.
May 22, 2022Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting.
May 22, 2022Hematol Oncol 2022; 40:716-723
Lalive d'Epinay Murielle, Güsewell Sabine, Graf Nicole, Mey Ulrich J M, Driessen Christoph, Hitz Felicitas
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos M, Richardson P, Bahlis N, Grosicki S, Cavo M, Beksac M, Legieć W, Liberati A, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach J, Petrucci M, Reece D, White D, Mateos M, Špička I, Lazaroiu M, Berdeja J, Kaufman J, Jou Y, Ganetsky A, Popa McKiver M, Lonial S, Weisel K, Driessen C. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2022; 9:e403-e414.
May 9, 2022Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
May 9, 2022Lancet Haematol 2022; 9:e403-e414
Dimopoulos Meletios A, Richardson Paul G, Bahlis Nizar, Grosicki Sebastian, Cavo Michele, Beksac Meral, Legieć Wojciech, Liberati Anna Marina, Goldschmidt Hartmut, Belch Andrew, Magen Hila, Larocca Alessandra, Laubach Jacob, Petrucci Maria Teresa, Reece Donna, White Darrell, Mateos Maria-Victoria, Špička Ivan, Lazaroiu Mihaela, Berdeja Jesus G, Kaufman Jonathan L, Jou Ying-Ming, Ganetsky Alex, Popa McKiver Mihaela, Lonial Sagar, Weisel Katja, Driessen Christoph
Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.
Besse A, Kraus M, Mendez-Lopez M, Maurits E, Overkleeft H, Driessen C, Besse L. Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors. Cells 2022; 11
Mar 1, 2022Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.
Mar 1, 2022Cells 2022; 11
Besse Andrej, Kraus Marianne, Mendez-Lopez Max, Maurits Elmer, Overkleeft Herman S, Driessen Christoph, Besse Lenka
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Berner F, Niederer R, Luimstra J, Pop O, Jochum A, Purde M, Hasan Ali O, Bomze D, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Dubbelaar M, Abdou M, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser D, Ludewig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee H, Walz J, Neefjes J, Flatz L. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. Oncoimmunology 2021; 10:2006893.
Nov 27, 2021Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Nov 27, 2021Oncoimmunology 2021; 10:2006893
Berner Fiamma, Niederer Rebekka, Luimstra Jolien J, Pop Oltin Tiberiu, Jochum Ann-Kristin, Purde Mette-Triin, Hasan Ali Omar, Bomze David, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Dubbelaar MariLisa, Abdou Marie-Therese, Baumgaertner Petra, Appenzeller Christina, Cicin-Sain Caroline, Lenz Tobias, Speiser Daniel E, Ludewig Burkhard, Driessen Christoph, Jörger Markus, Früh Martin, Jochum Wolfram, Cozzio Antonio, Rammensee Hans-Georg, Walz Juliane, Neefjes Jacques, Flatz Lukas
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Schreder M, Abildgaard N, Hájek R, Zojer N, Kastritis E, Broijl A, Schjesvold F, Boccadoro M, Caers J, Delforge M, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos M, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos M, Gay F, Einsele H, Terpos E. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol 2021; 8:e934-e946.
Oct 28, 2021COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Oct 28, 2021Lancet Haematol 2021; 8:e934-e946
Ludwig Heinz, Weisel Katja, Jackson Graham, Garderet Laurent, van de Donk Niels, Leleu Xavier, Goldschmidt Hartmut, Beksac Meral, Nijhof Inger, Schreder Martin, Abildgaard Niels, Hájek Roman, Zojer Niklas, Kastritis Efstathios, Broijl Annemiek, Schjesvold Fredrik, Boccadoro Mario, Caers Jo, Delforge Michel, Sonneveld Pieter, Facon Thierry, San-Miguel Jesus, Avet-Loiseau Hervé, Mohty Mohamad, Mateos Maria-Victoria, Moreau Philippe, Cavo Michele, Pawlyn Charlotte, Zweegman Sonja, Engelhardt Monika, Driessen Christoph, Cook Gordon, Dimopoulos Melitios A, Gay Francesca, Einsele Hermann, Terpos Evangelos
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
Bolomsky A, Caers J, Hübl W, Schreder M, Zojer N, Driessen C, Tang J, Besse L, Heckman C, Kubicek S, Hannich J, Miettinen J, Malyutina A, Besse A, Huber J, Fellinger S, Breid H, Parsons A, Klavins K, Ludwig H. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Adv 2021; 5:4125-4139.
Oct 26, 2021Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
Oct 26, 2021Blood Adv 2021; 5:4125-4139
Bolomsky Arnold, Caers Jo, Hübl Wolfgang, Schreder Martin, Zojer Niklas, Driessen Christoph, Tang Jing, Besse Lenka, Heckman Caroline A, Kubicek Stefan, Hannich J Thomas, Miettinen Juho J, Malyutina Alina, Besse Andrej, Huber Julia, Fellinger Stefanie, Breid Helene, Parsons Alun, Klavins Kristaps, Ludwig Heinz
High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors
Besse L, Besse A, Kraus M, Maurits E, Overkleeft H, Bornhauser B, Bourquin J, Driessen C. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors. Cells 2021; 10
Oct 22, 2021High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors
Oct 22, 2021Cells 2021; 10
Besse Lenka, Besse Andrej, Kraus Marianne, Maurits Elmer, Overkleeft Herman S, Bornhauser Beat, Bourquin Jean-Pierre, Driessen Christoph
Complete hematological and major molecular response through treatment with low-dose Interferon alpha 2a in high-risk polycythemia vera patient: a case report
Driessen C, Noppen C, Boonen G, Drewe J. Complete hematological and major molecular response through treatment with low-dose Interferon alpha 2a in high-risk polycythemia vera patient: a case report. Clin Case Rep 2021; 9:e04903.
Oct 6, 2021Complete hematological and major molecular response through treatment with low-dose Interferon alpha 2a in high-risk polycythemia vera patient: a case report
Oct 6, 2021Clin Case Rep 2021; 9:e04903
Driessen Christoph, Noppen Christoph, Boonen Georg, Drewe Juergen
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
Sonneveld P, Driessen C, Pour L, Levin M, Bos G, Ypma P, Wu K, van de Velden V, Oliva S, Broijl A, Croockewit A, Boccadoro M, Spencer A, Palumbo G, Offidani M, van de Donk N, Hveding C, Waage A, Minnema M, Troia R, Cornelisse P, Zamagni E, Zander T, Zweegman S, Ludwig H, Aquino S, van der Holt B, Beksac M, Dimopoulos M, Wester R, Hájek R, Gulbrandsen N, Gregersen H, Morelli A, De Rosa L, Cafro A, Gay F, Dozza L, Pantani L, Cavo M. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. J Clin Oncol 2021; 39:3613-3622.
Sep 14, 2021Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
Sep 14, 2021J Clin Oncol 2021; 39:3613-3622
Sonneveld Pieter, Driessen Christoph, Pour Luca, Levin Mark-David, Bos Gerard, Ypma Paula F, Wu KaLung, van de Velden Vincent, Oliva Stefania, Broijl Annemiek, Croockewit Alexandra, Boccadoro Mario, Spencer Andrew, Palumbo Giuseppe A, Offidani Massimo, van de Donk Niels W C J, Hveding Cecilie, Waage Anders, Minnema Monique C, Troia Rosella, Cornelisse Petra, Zamagni Elena, Zander Thilo, Zweegman Sonja, Ludwig Heinz, Aquino Sara, van der Holt Bronno, Beksac Meral, Dimopoulos Meletios A, Wester Ruth, Hájek Roman, Gulbrandsen Nina, Gregersen Henrik, Morelli Annamaria, De Rosa Luca, Cafro AnneMaria, Gay Francesca, Dozza Luca, Pantani Lucia, Cavo Michele
Carfilzomib-induced acute cardiotoxicity is mediated through angiotensin and caused by cardiomyocyte energy depletion
Mendez-Lopez M, Besse A, Florea B, Zuppinger C, Overkleeft H, Besse L, Driessen C (2021). Carfilzomib-induced acute cardiotoxicity is mediated through angiotensin and caused by cardiomyocyte energy depletion.
Sep 8, 2021Carfilzomib-induced acute cardiotoxicity is mediated through angiotensin and caused by cardiomyocyte energy depletion
Sep 8, 202118th International Myeloma Workshop
Mendez-Lopez Max, Besse Andrej, Florea Bogdan, Zuppinger Christian, Overkleeft Herman S, Besse Lenka, Driessen Christoph
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Besse L, Bolomsky A, Ludwig H, Hannich J, Loguinov A, Everts B, Berkers C, Pilon M, Farhan H, Vulpe C, Overkleeft H, Huber J, Ståhlman M, Borén J, Besse A, Stolze S, Sobh A, Zaal E, van der Ham A, Ruiz M, Phuyal S, Büchler L, Sathianathan M, Florea B, Driessen C. Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma. Cancer Res 2021; 81:4581-4593.
Jun 22, 2021Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Jun 22, 2021Cancer Res 2021; 81:4581-4593
Besse Lenka, Bolomsky Arnold, Ludwig Heinz, Hannich J Thomas, Loguinov Alex, Everts Bart, Berkers Celia R, Pilon Marc, Farhan Hesso, Vulpe Christopher D, Overkleeft Herman S, Huber Julia, Ståhlman Marcus, Borén Jan, Besse Andrej, Stolze Sara C, Sobh Amin, Zaal Esther A, van der Ham Alwin J, Ruiz Mario, Phuyal Santosh, Büchler Lorina, Sathianathan Marc, Florea Bogdan I, Driessen Christoph
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
Byrgazov K, Besse A, Kraus M, Slipicevic A, Lehmann F, Driessen C, Besse L. Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells. Hemasphere 2021; 5:e602.
Jun 12, 2021Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
Jun 12, 2021Hemasphere 2021; 5:e602
Byrgazov Konstantin, Besse Andrej, Kraus Marianne, Slipicevic Ana, Lehmann Fredrik, Driessen Christoph, Besse Lenka